Research programme: osteoporosis therapy - Genome Therapeutics/Amgen
Alternative Names: Osteoporosis therapy research programme - Genome Therapeutics/AmgenLatest Information Update: 23 Jan 2004
At a glance
- Originator Amgen; Oscient Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 09 Jan 2004 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
- 06 Jan 2003 Early research for Postmenopausal osteoporosis in USA (unspecified route)